Bausch + Lomb and Novaliq have submitted a new drug application for NOV03 to the FDA for the treatment of signs and symptoms dry eye disease associated with meibomian gland dysfunction, according to a press release.
NOV03 (perfluorohexyloctane) ophthalmic solution has been investigated in the phase 2 SEECASE trial, the phase 3 GOBI trial, the phase 3 MOJAVE trial and the KALAHARI safety extension trial in participants with dry eye disease associated with meibomian gland dysfunction.
“If approved by the FDA, NOV03 will be the first available therapy indicated to address the signs and